Hudson Marie, Steele Russell, Taillefer Suzanne, Baron Murray
Sir Mortimer B. Davis Jewish General Hospital and McGill University, Montreal, Quebec, Canada.
Arthritis Rheum. 2008 Feb 15;59(2):270-8. doi: 10.1002/art.23343.
To determine the validity of the World Health Organization Disability Assessment Schedule II (WHODAS II) in systemic sclerosis (SSc).
Patients enrolled in the Canadian Scleroderma Research Group registry participated in a standardized evaluation and completed the WHODAS II. Criterion validity was assessed by comparing the WHODAS II with the Medical Outcomes Study Short Form 36 (SF-36), construct validity was assessed by examining how it relates to common measures of outcome in SSc, and discriminative validity was assessed by examining how it distinguishes patients with more severe disease from those with less severe disease.
A total of 402 patients with SSc were included (mean +/- SD age 55 +/- 13 years, 87% women, mean +/- SD disease duration 11 +/- 9 years). The mean +/- SD WHODAS II score was 24.6 +/- 17.4, and the greatest impairments were in life activities and mobility. There were moderate to good correlations between the WHODAS II and the SF-36 Physical Component Summary score (r = -0.44), the SF-36 Mental Component Summary score (r = -0.41), and measures of function (r = 0.54), depression (r = 0.44), pain (r = 0.40), and fatigue (r = -0.49, P < 0.0001 for all). The WHODAS II was able to consistently distinguish patients with milder disease from those with more severe disease.
The WHODAS II had good psychometric properties in patients with SSc and should be considered a valid measure of health-related quality of life in SSc.
确定世界卫生组织残疾评定量表第二版(WHODAS II)在系统性硬化症(SSc)中的有效性。
纳入加拿大硬皮病研究组登记处的患者参与标准化评估并完成WHODAS II。通过将WHODAS II与医学结局研究简明健康调查问卷36项版本(SF - 36)进行比较来评估效标效度,通过检查其与SSc常见结局指标的关系来评估结构效度,通过检查其如何区分疾病较轻和较重的患者来评估区分效度。
共纳入402例SSc患者(平均±标准差年龄55±13岁,87%为女性,平均±标准差病程11±9年)。WHODAS II评分的平均±标准差为24.6±17.4,最大损伤在于生活活动和移动性。WHODAS II与SF - 36身体成分汇总评分(r = -0.44)、SF - 36心理成分汇总评分(r = -0.41)以及功能指标(r = 0.54)、抑郁(r = 0.44)、疼痛(r = 0.40)和疲劳(r = -0.49,所有P < 0.0001)之间存在中度至良好的相关性。WHODAS II能够持续区分疾病较轻和较重的患者。
WHODAS II在SSc患者中具有良好的心理测量学特性,应被视为评估SSc患者健康相关生活质量的有效指标。